Analysis of the iron states in iron-containing pharmaceutical products using Mossbauer spectroscopy

被引:1
作者
Alenkina, Irina, V [1 ]
Chukin, Andrey, V [1 ]
Leitus, Gregory [2 ]
Denisova, Olga, V [1 ]
Gracheva, Maria [3 ,4 ]
Felner, Israel [5 ]
Kuzmann, Erno [3 ]
Homonnay, Zoltan [3 ]
Oshtrakh, Michael I. [1 ]
机构
[1] Ural Fed Univ, Inst Phys & Technol, Ekaterinburg 620002, Russia
[2] Weizmann Inst Sci, Dept Chem Res Support, Rehovot, Israel
[3] Eotvos Lorand Univ, Inst Chem, Lab Nucl Chem, Budapest, Hungary
[4] Eotvos Lorand Univ, Hevesy Gyorgy Doctoral Sch Chem, Budapest, Hungary
[5] Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel
关键词
Iron-containing pharmaceuticals; Iron state; Mossbauer spectroscopy; X-ray diffraction; Magnetization measurements; DIETARY-SUPPLEMENTS; FERROUS FUMARATE; THERMAL-DECOMPOSITION; CONTAINING VITAMINS; PARAMETERS;
D O I
10.1016/j.jpba.2023.115745
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Iron-containing pharmaceuticals, namely: (i) PreNatal with ferrous fumarate, (ii) Tardyferon (R) with ferrous sulfate, (iii) Fenules with water free ferrous sulfate, (iv) Iron Complex with iron glycinate, citrate, (v) Gentle Iron, (vi) Hema-Plex (R) and (vii) Iron Bisglycinate with iron (ferrous) bisglycinate chelate (iron compounds are given as declared by the manufactures) were studied by Fe-57 Mossbauer spectroscopy with X-ray diffraction and magnetization measurements for analysis of the iron state. The obtained results demonstrate that the iron compound announced by the manufacturer in each pharmaceutical is not homogeneous and exists as some modifications of this compound or results of its transformation/oxidation probably due to its instability. The presence of ferrous and ferric compounds is observed, and the relative ferric iron fractions are roughly determined for each pharmaceutical product. This analysis clearly shows the differences between the iron compounds proclaimed by the manufacturers and those obtained by Mo center dot ssbauer spectroscopy. That justifies as to why this technique should be used for the control and analysis of the iron-containing pharmaceuticals.
引用
收藏
页数:15
相关论文
共 35 条
[11]   Safety evaluation of ferrous bisglycinate chelate [J].
Jeppsen, RB ;
Borzelleca, JF .
FOOD AND CHEMICAL TOXICOLOGY, 1999, 37 (07) :723-731
[12]   Stability of Ferrous Fumarate in Medicaments for Women: Application of Mossbauer Spectroscopy [J].
Kadziolka-Gawel, M. ;
Wojtyniak, M. .
ACTA PHYSICA POLONICA A, 2016, 129 (06) :1242-1244
[13]  
Kadziolka-Gawel M, 2015, ACTA PHYS POL A, V127, P653, DOI 10.12693/APhysPolA.127.653
[14]  
Kamnev AA, 2013, MOSSBAUER SPECTROSCO, P272
[15]   User-friendly software for Mossbauer spectrum analysis [J].
Klencsar, Z ;
Kuzmann, E ;
Vertes, A .
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY-ARTICLES, 1996, 210 (01) :105-118
[16]  
Kuzmann E., 2011, Handbook of Nuclear Chemistry, P1379, DOI 10.1007/978-1-4419-0720-2_25
[17]   Comparison of a combination ferrous fumarate product and a polysaccharide iron complex as oral treatments of iron deficiency anemia: A Taiwanese study [J].
Liu, TC ;
Lin, SF ;
Chang, CS ;
Yang, WC ;
Chen, TP .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 80 (05) :416-420
[18]  
Murad E., 2004, MOSSBAUER SPECTROSCO
[19]   MOSSBAUER SPECTROSCOPIC AND DC ELECTRICAL-CONDUCTIVITY STUDY OF THE THERMAL-DECOMPOSITION OF SOME IRON(II) DICARBOXYLATES [J].
NIKUMBH, AK ;
PHADKE, MM ;
DATE, SK ;
BAKARE, PP .
THERMOCHIMICA ACTA, 1994, 239 :253-268
[20]  
OLOWE AA, 1991, HYPERFINE INTERACT, V68, P253